Clinical trials: B Cell
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that severely affected chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab…
- Trial name
- NCT01156922
- Testing
- Rituximab
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Haukeland University Hospital
HIV-1-infection
Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens
The objective of this experimental medicine study is to determine the extent to which different prime-boost combinations influence serum neutralising antibody breadth and associated B and T cells responses.
- Trial name
- EAVI2020_01 (NCT03816137)
- Testing
- ConM SOSIP, EDC ConM SOSIP, ConS UFO
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. Etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH): Etoposide…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma
- Trial name
- NCT00001337
- Testing
- Etoposide, Rituximab, Prednisone
- Where
- 5 sites in United States
- Volunteers
- 348 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Leukemia, Myelodysplastic Syndromes
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients who have…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00004245
- Testing
- sodium salicylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well E7389 works in treating patients with recurrent or progressive stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00400829
- Testing
- eribulin mesylate
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL)
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19/CD22)-T cells in patients with relapsed or refractory B-cell lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma
- Trial name
- NCT07168291
- Testing
- Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
- Where
- China
- Volunteers
- 3 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This phase I/II trial studies whether a new kind of blood stem cell (bone marrow) transplant, that may be less toxic, is able to treat underlying blood cancer. Stem cells are "seed cells" necessary to make blood cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome
- Trial name
- NCT00027820
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Transplants and Implants
B-Cell Targeted Carfilzomib Desensitization
The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.
- Trial name
- NCT02442648
- Testing
- Carfilzomib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- E. Steve Woodle
Lymphoma
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00005040
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Burkitt Lymphoma, Non-Hodgkins Lymphoma
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
- Conditions
- Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
- Trial name
- NCT00126191
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
The objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who showed newly emerging or persistent MRD after a…
- Conditions
- ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory
- Trial name
- Anti-CD19-ALL (NCT05366218)
- Testing
- Tafasitamab
- Where
- 11 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-R) on…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Diffuse
- Trial name
- NCT00455897
- Testing
- GM-CSF, CHOP, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) in adult patients with B cell malignancies after failure of autologous chimeric antigen receptor T…
- Trial name
- NCT05640713
- Testing
- ThisCART19A, Fludarabine Pill, Cyclophosphamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Henan Cancer Hospital
Leukemia, Lymphoproliferative Disorders
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
The goal of this clinical research study is to learn the highest tolerable dose of phenethyl isothiocyanate (PEITC) that can be given to patients who have a lymphoproliferative disorder that has been treated with fludarabine.
- Trial name
- NCT00968461
- Testing
- Phenethyl Isothiocyanate (PEITC)
- Sponsor
- M.D. Anderson Cancer Center
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
B-cell Lymphoma
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
This is an open label, multicenter, dose escalation, phase Ib study to determine the recommended dose by assessing the maximum tolerated dose (MTD), safety and efficacy of ibrutinib in combination with R-DHAP (Group A/Abis) or…
- Trial name
- BIBLOS (NCT02055924)
- Testing
- Ibrutinib and immunochemotherapies
- Where
- 15 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- The Lymphoma Academic Research Organisation
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.